Reuters (7/18, Sunny, Mahatole) reported the FDA’s “panel of independent advisers on Friday voted against the efficacy of Otsuka Pharma’s antipsychotic drug in combination with Viatris’ antidepressant Zoloft [sertraline hydrochloride] for treating adults with PTSD.” The FDA “panel voted 10-1 to say the available data does not establish the efficacy of the drug, brexpiprazole, in combination with Zoloft…for treating the condition.” The panel’s “decision is in line with the FDA staff reviewers’ assessment on Wednesday.

Related Links:

— “US FDA advisers recommend against Otsuka’s PTSD combination treatment,”Mariam E Sunny and Siddhi Mahatole, Reuters, July 18, 2025

HealthDay (7/18, Thompson ) reported, “Some women have a greater risk of depression as they go through premature menopause, according to a new study.” Researchers found that “women were at greater risk for depression if they entered premature menopause earlier; their condition had a genetic cause; or they experienced worse menopause symptoms.” Study results indicate that “women grieving the loss of their fertility or without sufficient emotional support also had a higher risk.” The findings were published in Menopause.

Related Links:

— “Depression Risk Greater In Some Women With Premature Menopause,”
Dennis Thompson , HealthDay, July 18, 2025

CNN (7/17, Howard ) reports, “The 988 Suicide & Crisis Lifeline’s specialized services for LGBTQ+ youth have officially ended operations, meaning people contacting 988 for help no longer have the option to ‘press 3’ to reach counselors specifically trained to respond to the needs of this group.” According to CNN, “The lifeline included a subnetwork for LGBTQ+ youth soon after its launch in July 2022.” However, “the US Department of Health and Human Services’ Substance Abuse and Mental Health Services Administration…announced last month that those services would be coming to an end.”

Related Links:

— “Trump administration ends 988 Suicide & Crisis Lifeline’s specialized service for LGBTQ+ youth,”Jacqueline Howard , CNN, July 17, 2025

HealthDay (7/17, Gotkine ) reports, “Most individuals do not go through severe withdrawal after discontinuing antidepressants,according to a study.” One researcher said, “Despite previous concern about stopping antidepressants, our work finds that most people do not experience severe withdrawal, in terms of additional symptoms. Importantly, depression relapse was not linked to antidepressant withdrawal in these studies.” The findings were published in JAMA Psychiatry.

Related Links:

— “Few Discontinuation Symptoms Reported After Stopping Antidepressants,”
Elana Gotkine , HealthDay, July 17, 2025

Reuters (7/16, Niasse ) reports, “More than half of large U.S. employers plan to scale back health care benefits next year as rising costs from weight-loss and specialty drugs squeeze budgets, according to a new survey [PDF] released by consulting firm Mercer on Wednesday.” The survey found that “among employers with 500 or more workers, 51% said they planned to increase cost-sharing in 2026, including raising deductibles and maximum out-of-pocket costs for workers.” That percentage “is up from 45% of large employers who said they would increase cost-sharing for 2025.”

Related Links:

— “Many US employers plan to pare health benefits as weight-loss spending soars,” Amina Niasse, Reuters, July 16, 2025